BiotechTube
Home/Immatics/Cedrik Britten, M.D., Ph.D.
CB

Cedrik Britten, M.D., Ph.D.

Chief Medical Officer

Immatics

Therapeutic Areas

OncologySolid Tumors

Immatics Pipeline

DrugIndicationPhase
IMA203CD8PRAME-positive solid tumorsPhase 1b
IMA203PRAME-positive solid tumorsPhase 1a
IMA402 (TCER®)PRAME-positive solid tumorsPhase 1/2
Anzu-cel (IMA203C)PRAME-positive solid tumorsPhase 1
IMA401 (TCER®)MAGEA4/8-positive solid tumorsPhase 1/2

Leadership Team at Immatics

HS
Harpreet Singh, Ph.D.
Chief Executive Officer
CR
Carsten Reinhardt, M.D., Ph.D.
Chief Development Officer
VR
Venkat Ramanan, Ph.D.
Chief Financial Officer
SW
Steffen Walter, Ph.D.
Chief Operating Officer
TW
Toni Weinschenk, Ph.D.
Chief Innovation Officer
RK
Rainer Kramer, Ph.D.
Chief Business Officer & Site Head Munich
ES
Edward Sturchio, J.D.
General Counsel
PC
Peter Chambré
Chairman of the Board of Directors
HL
Heather L. Mason
Vice Chair of the Board of Directors
View full Immatics profile